Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Pharmacokinetic Profile of Single Dose of JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) Injection in Healthy Volunteers

NCT04220073 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT04220073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04220073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Pharmacokinetic Profile of Single Dose of JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) Injection in Healthy Volunteers
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 17, 2020
Completion date
November 20, 2020
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tolerability, safety, immunogenicity and pharmacokinetic of js005